Back to top
more

McKesson (MCK)

(Real Time Quote from BATS)

$589.88 USD

589.88
515,500

+4.14 (0.71%)

Updated Jul 24, 2024 03:55 PM ET

After-Market: $590.28 +0.40 (0.07%) 4:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Indrajit Bandyopadhyay headshot

5 Dental Supplies Stocks to Buy Amid Recovering Prospects

by Indrajit Bandyopadhyay

Here, we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors - MCK, ABC, LH, CAH and MMSI.

Cardinal Health (CAH) Q2 Earnings Top, EPS Outlook Raised

by Zacks Equity Research

Cardinal Health's (CAH) fiscal second-quarter results benefit from the solid performance of the Pharmaceutical segment.

Accuray (ARAY) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Despite solid product demand, Accuray (ARAY) reports an overall soft fiscal Q2 performance.

BD (BDX) Q1 Earnings and Revenues Beat Estimates, Margins Down

by Zacks Equity Research

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.

Quest Diagnostics (DGX) Q4 Earnings Top Estimates, Margin Down

by Zacks Equity Research

Improvement within Quest Diagnostics' (DGX) legacy base business contributes to Q4 performance.

McKesson (MCK) Q3 Earnings Surpass Estimates, EPS View Up

by Zacks Equity Research

McKesson's (MCK) third-quarter fiscal 2023 results benefit from segmental growth.

Align Technology (ALGN) Q4 Earnings Top Estimates, Margins Drop

by Zacks Equity Research

Align Technology's (ALGN) lower scanner volume and ASPs are partially offset by higher services revenues from the larger installed base of scanners and increased non-system revenues.

AmerisourceBergen (ABC) Q1 Earnings Top, EPS View Raised

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal first-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.

McKesson (MCK) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

McKesson (MCK) delivered earnings and revenue surprises of 8.83% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Boston Scientific (BSX) Q4 Earnings Miss, Operating Margin Up

by Zacks Equity Research

Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in the fourth quarter of 2022.

Henry Schein (HSIC) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) dental business is likely to have gained in Q4 from the acquisition of Midway Dental.

Are Investors Undervaluing Laboratory Corp. of America (LH) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Medical Stocks Lagging McKesson (MCK) This Year?

by Zacks Equity Research

Here is how McKesson (MCK) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year.

Stryker's (SYK) Q4 Earnings Beat Estimates, Volume Improves

by Zacks Equity Research

Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs adversely impact margins.

Philips' (PHG) Q4 Earnings Down Y/Y, Supply Chain Issues Ease

by Zacks Equity Research

Koninklijke Philips' (PHG) Q4 top and bottom-line results reflect easing supply chain constraints.

LabCorp (LH) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Ongoing sales rebound in the base business for the Diagnostics and Drug Development segments likely drive LabCorp (LH) Q4 revenues.

Baxter (BAX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) fourth-quarter results are likely to reflect growth in elective surgical procedures, offset by currency and supply challenges. Hillrom's products are likely to have boosted sales.

Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ONEV

Shaun Pruitt headshot

2 Medical Stocks to Consider Buying Before Earnings

by Shaun Pruitt

There is a continued need for prosperous healthcare companies, here are two medical stocks investors may want to consider buying ahead of earnings this week.

BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have driven up Q1 sales.

Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Sustained sales gains in terms of the Bio-Rads (BIO) process media, western blotting, Droplet Digital PCR and qPCR products are likely to drive Q4 revenues.

Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) second-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.

McKesson (MCK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, McKesson (MCK) closed at $379.20, marking a -1.28% move from the previous day.

ResMed's (RMD) Q2 Earnings Beat Estimates, Margins Falls

by Zacks Equity Research

ResMed's (RMD) mask sales growth was strong across the globe, reflecting a post-COVID pandemic awareness about the importance and need for respiratory hygiene and respiratory health.